AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Acemetacin is used to alleviate pain associated with various conditions, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, musculoskeletal disorders, and acute pain following injury or surgery. It works by inhibiting the synthesis of prostaglandins, which are substances involved in inflammation and pain perception.
Anti-inflammatory Effects: Acemetacin has anti-inflammatory properties, which make it effective in reducing inflammation and swelling associated with arthritis and other inflammatory conditions. By inhibiting the enzyme cyclooxygenase (COX), acemetacin suppresses the production of inflammatory mediators called prostaglandins, thereby attenuating the inflammatory response.
Management of Osteoarthritis: Acemetacin is commonly prescribed for the symptomatic treatment of osteoarthritis, a degenerative joint disease characterized by cartilage breakdown, joint inflammation, and pain. It helps improve joint function, reduce pain, and increase mobility in individuals with osteoarthritis, although it does not alter the course of the disease.
Treatment of Rheumatoid Arthritis: Acemetacin may also be used in the treatment of rheumatoid arthritis, an autoimmune inflammatory disorder that affects the joints and other tissues in the body. It helps alleviate joint pain, stiffness, and swelling, and may improve overall quality of life in patients with rheumatoid arthritis when used as part of a comprehensive treatment regimen.
Musculoskeletal Disorders: Acemetacin is effective in the management of various musculoskeletal disorders, including tendonitis, bursitis, and acute soft tissue injuries. It provides symptomatic relief from pain and inflammation, allowing individuals to resume normal activities and function.
Dosage and Administration: Acemetacin is typically administered orally in the form of tablets or capsules. The dosage and frequency of administration may vary depending on the patient's age, weight, medical condition, and response to treatment. It is usually taken with food or milk to minimize gastrointestinal side effects.
Gastrointestinal Effects: Like other NSAIDs, acemetacin may cause gastrointestinal side effects, including dyspepsia (indigestion), heartburn, nausea, vomiting, abdominal pain, and gastrointestinal ulcers or bleeding. Patients with a history of peptic ulcer disease, gastrointestinal bleeding, or other gastrointestinal disorders may be at increased risk of experiencing these adverse effects.
Cardiovascular Risks: NSAIDs, including acemetacin, may be associated with an increased risk of cardiovascular events such as heart attack or stroke, particularly when used at high doses or for prolonged periods. Patients with pre-existing cardiovascular disease, hypertension, or other risk factors for cardiovascular events should use acemetacin with caution and under close medical supervision.
Renal Effects: Acemetacin can impair renal function and may cause renal toxicity, including acute kidney injury, electrolyte imbalances, and fluid retention. Patients with pre-existing renal impairment, dehydration, or heart failure may be at increased risk of renal adverse effects when taking acemetacin.
Contraindications: Acemetacin is contraindicated in individuals with a history of hypersensitivity to NSAIDs, aspirin, or other related medications, as well as those with a history of asthma, urticaria, or other allergic reactions precipitated by NSAIDs. It should be used with caution in patients with renal or hepatic impairment, gastrointestinal disorders, or cardiovascular disease.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
Acne | 0.3 | 0.3 | |
ADHD | 2.4 | 0.3 | 7 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
Allergic Rhinitis (Hay Fever) | 1.3 | 1.2 | 0.08 |
Allergies | 3.1 | 1.9 | 0.63 |
Allergy to milk products | 0.9 | 0.9 | 0 |
Alopecia (Hair Loss) | 0.1 | 0.1 | |
Alzheimer's disease | 4 | 3.2 | 0.25 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.6 | 1.67 |
Ankylosing spondylitis | 1.6 | 0.9 | 0.78 |
Anorexia Nervosa | 0.7 | 2.2 | -2.14 |
Antiphospholipid syndrome (APS) | 0.8 | 0.8 | |
Asthma | 2.7 | 1.5 | 0.8 |
Atherosclerosis | 1.4 | 1.1 | 0.27 |
Atrial fibrillation | 1.4 | 1 | 0.4 |
Autism | 5.2 | 3.7 | 0.41 |
Autoimmune Disease | 0.9 | 0.5 | 0.8 |
Barrett esophagus cancer | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1.4 | 1.4 | |
Bipolar Disorder | 1.5 | 1.1 | 0.36 |
Brain Trauma | 0.3 | 1.1 | -2.67 |
Breast Cancer | 0.5 | 0.3 | 0.67 |
Cancer (General) | 0.6 | 0.2 | 2 |
Carcinoma | 2.9 | 1 | 1.9 |
Celiac Disease | 1.5 | 1.1 | 0.36 |
Cerebral Palsy | 0.7 | 1.3 | -0.86 |
Chronic Fatigue Syndrome | 3.4 | 1.6 | 1.13 |
Chronic Kidney Disease | 2 | 0.7 | 1.86 |
Chronic Lyme | 0.6 | 0.8 | -0.33 |
Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 1.1 | 0.36 |
Chronic Urticaria (Hives) | 1 | 0.7 | 0.43 |
Coagulation / Micro clot triggering bacteria | 1 | 1.3 | -0.3 |
Cognitive Function | 1.8 | 1.1 | 0.64 |
Colorectal Cancer | 6.3 | 1.2 | 4.25 |
Constipation | 1.2 | 0.7 | 0.71 |
Coronary artery disease | 1.3 | 1.6 | -0.23 |
COVID-19 | 4.4 | 5.1 | -0.16 |
Crohn's Disease | 4.6 | 2.6 | 0.77 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 0.7 | 1 | -0.43 |
d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
deep vein thrombosis | 2.6 | 1.4 | 0.86 |
Denture Wearers Oral Shifts | 0.8 | 0.8 | |
Depression | 6.2 | 3.2 | 0.94 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 1.2 | 0.8 | 0.5 |
Endometriosis | 1.4 | 1.2 | 0.17 |
Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
Epilepsy | 2.2 | 0.8 | 1.75 |
erectile dysfunction | 1.2 | 1.2 | |
Fibromyalgia | 1 | 1 | 0 |
Functional constipation / chronic idiopathic constipation | 2.5 | 2 | 0.25 |
gallstone disease (gsd) | 1.5 | 1 | 0.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.6 | 0.83 |
Generalized anxiety disorder | 2.1 | 1.2 | 0.75 |
Glioblastoma | 0.3 | -0.3 | |
Gout | 1.4 | 0.4 | 2.5 |
Graves' disease | 0.6 | 1.6 | -1.67 |
Gulf War Syndrome | 0.4 | 1.1 | -1.75 |
Halitosis | 1.2 | 0.3 | 3 |
Hashimoto's thyroiditis | 2.1 | 0.4 | 4.25 |
Heart Failure | 2.5 | 1.1 | 1.27 |
hemorrhagic stroke | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.9 | 0.9 | |
High Histamine/low DAO | 0.6 | 0.3 | 1 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.2 | 1 |
hyperglycemia | 1.4 | 0.8 | 0.75 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 2 | 2.7 | -0.35 |
Hypothyroidism | 0.1 | 0.4 | -3 |
Hypoxia | 1.1 | 0.1 | 10 |
IgA nephropathy (IgAN) | 1.5 | 1.7 | -0.13 |
Inflammatory Bowel Disease | 4.1 | 4.1 | 0 |
Insomnia | 0.9 | 1.9 | -1.11 |
Intelligence | 1 | 0.1 | 9 |
Intracranial aneurysms | 1 | 1 | |
Irritable Bowel Syndrome | 4 | 2.5 | 0.6 |
ischemic stroke | 1.2 | 1.4 | -0.17 |
Liver Cirrhosis | 3.8 | 2.8 | 0.36 |
Long COVID | 3.1 | 3.3 | -0.06 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.8 | 0.7 | 0.14 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 1.3 | 0.3 | 3.33 |
ME/CFS with IBS | 0.5 | 0.6 | -0.2 |
ME/CFS without IBS | 0.8 | 0.3 | 1.67 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 0.4 | 0.7 | -0.75 |
Metabolic Syndrome | 3.9 | 3.5 | 0.11 |
Mood Disorders | 6.3 | 2.8 | 1.25 |
multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
Multiple Sclerosis | 3.3 | 2 | 0.65 |
Multiple system atrophy (MSA) | 1 | 0.4 | 1.5 |
myasthenia gravis | 0.9 | 0.5 | 0.8 |
neuropathic pain | 0.3 | 1.3 | -3.33 |
Neuropathy (all types) | 0.8 | 1.4 | -0.75 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3 | 2.3 | 0.3 |
NonCeliac Gluten Sensitivity | 1 | 0.3 | 2.33 |
Obesity | 4.4 | 4.3 | 0.02 |
obsessive-compulsive disorder | 3.9 | 1.3 | 2 |
Osteoarthritis | 1.9 | 1 | 0.9 |
Osteoporosis | 2 | 1 | 1 |
pancreatic cancer | 1 | 0.3 | 2.33 |
Parkinson's Disease | 5.4 | 3.1 | 0.74 |
Polycystic ovary syndrome | 3.8 | 2.6 | 0.46 |
Premenstrual dysphoric disorder | 0.1 | 0.1 | |
primary biliary cholangitis | 0.3 | 1.2 | -3 |
Primary sclerosing cholangitis | 1.5 | 0.8 | 0.88 |
Psoriasis | 1.3 | 1.2 | 0.08 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.6 | 1.9 | 0.89 |
Rosacea | 0.3 | 0.5 | -0.67 |
Schizophrenia | 2.7 | 1.4 | 0.93 |
scoliosis | 0.1 | 0.3 | -2 |
Sjögren syndrome | 1.4 | 1 | 0.4 |
Sleep Apnea | 0.7 | 1.6 | -1.29 |
Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 1 | |
Stress / posttraumatic stress disorder | 1.3 | 1.3 | 0 |
Systemic Lupus Erythematosus | 2.6 | 1.4 | 0.86 |
Tic Disorder | 0.9 | 0.1 | 8 |
Tourette syndrome | 0.4 | 0.3 | 0.33 |
Type 1 Diabetes | 2.4 | 1.5 | 0.6 |
Type 2 Diabetes | 4.4 | 3.7 | 0.19 |
Ulcerative colitis | 2.2 | 3.9 | -0.77 |
Unhealthy Ageing | 2.7 | 1 | 1.7 |
Vitiligo | 1.3 | 0.1 | 12 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]